Indaptus Therapeutics Inc INDP:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/14/24 EDT
2.19UNCH (UNCH)
Volume
2,243
52 week range
1.56 - 4.08
Loading...
  • Open2.12
  • Day High2.20
  • Day Low2.12
  • Prev Close2.12
  • 52 Week High4.08
  • 52 Week High Date09/19/23
  • 52 Week Low1.56
  • 52 Week Low Date02/13/24

Key Stats

  • Market Cap18.70M
  • Shares Out8.54M
  • 10 Day Average Volume0.01M
  • Dividend-
  • Dividend Yield-
  • Beta1.46
  • YTD % Change21.02

KEY STATS

  • Open2.12
  • Day High2.20
  • Day Low2.12
  • Prev Close2.12
  • 52 Week High4.08
  • 52 Week High Date09/19/23
  • 52 Week Low1.56
  • 52 Week Low Date02/13/24
  • Market Cap18.70M
  • Shares Out8.54M
  • 10 Day Average Volume0.01M
  • Dividend-
  • Dividend Yield-
  • Beta1.46
  • YTD % Change21.02

RATIOS/PROFITABILITY

  • EPS (TTM)-1.78
  • P/E (TTM)-1.23
  • Fwd P/E (NTM)-1.13
  • EBITDA (TTM)-15.865M
  • ROE (TTM)-98.06%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/12/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Indaptus Therapeutics Inc

 

Profile

MORE
Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company, which specializes in cancer and viral infection treatments. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single...
Roger Pomerantz M.D.
Independent Non-Executive Chairman of the Board
Jeffrey Meckler
Chief Executive Officer, Director
Walt Linscott Esq.
Chief Operating Officer
Nir Sassi
Chief Financial Officer, Treasurer, Secretary
Address
3 Columbus Circle, 15Th Floor
New York, NY
10019
United States